brain cancer

Australia-based Kazia Therapeutics Limited (NASDAQ: KZIA) announced final data from a Phase 2 study of paxalisib as first-line therapy in patients with glioblastoma. 60mg once daily was identified as the maximum tolerated dose (MTD) and selected for future studies.  Median...

VBI Vaccines Inc (NASDAQ: VBIV) has presented updated 12-month and 18-month overall survival (OS) data from the Phase 2a study of VBI-1901, the Company's recurrent glioblastoma (GBM) vaccine VBI-1901 + granulocyte-macrophage colony-stimulating factor (GM-CSF) arm showed 18-month...

Puma Biotechnology Inc (NASDAQ: PBYI) announced interim data from the neratinib arm of Phase 2 INSIGhT Trial in newly diagnosed unmethylated glioblastoma with IDH R132H mutation-negative.  In the intent-to-treat population, progression-free survival (PFS) was not significantly...

Plus Therapeutics Inc (NASDAQ: PSTV) released interim data from Phase 1 ReSPECT-GBM trial in patients with recurrent glioblastoma (GBM) of Rhenium-186 NanoLiposome (186RNL). According to the interim data, 186RNL delivered via convection-enhanced delivery (CED) was well-tolerated...

Novocure Ltd (NASDAQ: NVCR) has released updated data from the Phase 2 pilot 2-THE-TOP of Tumor Treating Fields (TTFields) together with pembrolizumab and temozolomide for newly diagnosed glioblastoma (GBM).  Of the 19 patients with follow-up over nine months, the median...

Kintara Therapeutics Inc (NASDAQ: KTRA) announced topline data results from the newly diagnosed adjuvant arm of its Phase 2 clinical study. The Phase 2 trial is testing VAL-083 in glioblastoma multiforme (GBM) patients who have an unmethylated promoter of the methylguanine DNA-...

PolyPid Ltd (NASDAQ: PYPD) has announced preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program. OncoPLEX is designed to provide controlled local exposure to docetaxel, one of the most widely used chemotherapy...

CNS Pharmaceuticals Inc (NASDAQ: CNSP) has opened enrollment for its Phase 2 study evaluating its lead candidate, Berubicin, for recurrent Glioblastoma Multiforme (GBM). The company intends to enroll approximately 210 subjects. The trial includes adult patients with...

Medicenna Therapeutics Corp (NASDAQ: MDNA) announced the peer-reviewed publication of clinical data from its Phase 2b trial evaluating MDNA55 in recurrent glioblastoma (rGBM). The Phase 2b trial evaluated MDNA55, an interleukin-4 (IL-4)-guided toxin, as a treatment for rGBM,...

Humanigen Inc (NASDAQ: HGEN) has announced results from the Phase 1 trial evaluating its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM), the most frequent and lethal primary brain cancer. The results will be presented as a poster at the...

By The Fresh Toast's Bendan Bures, provided exclusively to Benzinga Cannabis. Colorado State University researchers found that CBD caused cell death in glioblastoma, a rare and intractable form of brain cancer. Cannabidoil (CBD) has emerged in recent years as an alternative medicine for hard-to...